0750 GMT - Novartis's 2025 guidance is constructive and beats consensus expectations, Intron Health analysts say in a note. The Swiss pharma giant's guidance is for mid-to-high single-digit sales growth, which is a 3% lift to consensus sales and EBIT, the analysts say. "Whilst we were worried about the impact of foreign-currency effects, Part D reform [U.S. Medicare drug pricing reform] and [multiple-sclerosis drug] Kesimpta pricing, this guidance looks very strong and appears higher than consensus," they say.(helena.smolak@wsj.com)
(END) Dow Jones Newswires
January 31, 2025 02:50 ET (07:50 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.